|
-- back to lectures --
|
| |
| Course Title: |
|
A paradigm for Understanding the Pathogenesis of IBD, Emphasizing Host-Microbial Interactions |
|
|
|
| |
| |
Credit Hours: |
0.5 |
| Valid Until: |
02/31/2011 |
|
| |
Lecturer: |
Balfour Sartor, MD |
|
Date Released: |
2/22/2010 |
|
| |
Affiliation: |
Professor of Medicine
University of North Carolina
Center for Gastroenterology, Biology and Disease
Chapel Hill, NC |
| |
|
| |
View the Post-Test
|
| |
|
| |
| |
Lecture Overview: |
| |
| |
This lecture discusses the current understanding of pathogenesis of Crohn's disease and ulcerative colitis. 70-80 genes have been associated with these disorders, but it is clear that environmental factors, such as transient infections, diet, NSAIDs, stress and smoking, determine which genetically susceptible host develops disease. A subset of commensal bacteria provide the constant antigenic stimuli that activate effector TH1 and TH17 immune responses that cause Crohn's disease and the typical TH2 response that mediates ulcerative colitis. Another subset of bacteria provides protection. A developing paradigm for Crohn's disease is that defective bacterial killing by innate immune cells allows bacteria to activate effector TH1 and TH17 imune responses. |
| |
|
| |
| |
Target Audience: |
| |
| |
This activity is intended for Gastroenterology and select Internal Medicine healthcare professionals. |
| |
|
| |
| |
Objectives: |
| |
| |
Upon completion of this activity, participants should be better able to:- Review the current data on factors relevant to the pathogenesis of IBD and gain a better understanding of Crohn’s disease and ulcerative colitis.
- Evaluate the risk factors and the role of gene-environmental interactions for inflammatory bowel disease and their impact on patients’ outcome.
- Explore data on new and emerging approaches for individualized therapy for IBD subtypes and their possible role; an approach of different pathogenesis to different therapy.
|
| |
|
| |
| |
Lecturer Biography: |
| |
| |
During his career, Dr. Sartor has received numerous awards including an NIH Senior Fellowship award and has sat upon many committee and charitable foundation boards including the Crohn's and Colitis Foundation of America. A former Senior Editor of Gastroenterlogy, a medical journal, he has published well over 150 peer-reviewed journal articles. Currently, Dr. Sartor is active in at least 11 GI-related research projects at his Chapel Hill facilities. |
| |
|
| |
| |
Lecturer Disclosure Statement: |
| |
| |
Dr. Sartor has received honoraria for Advisory Board/Advisory Panel roles for Danone-Yakult, UCB, Proctor & Gamble, McNeil Pharmaceuticals and Takeda Pharmaceuticals |
| |
|
| |
| |
Accreditation Statement: |
| |
| |
Medical Education Conferences, Inc. designates this educational activity for a maximum of 0.5 AMA PRA Category 1 credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. |
| |
|
|
|
